Palatin Technologies, Inc. · AMEX:PTN
Palatin Technologies — Cowen and Company 29th Annual Health Care Conference (March 2009)
30 slides from Palatin Technologies's conference presentation, Mar 19, 2009
Slide 1: Cowen and Company Annual Health Care Conference
<> PALATIN TECHNOLOGIES Cowen and Company 29¢* Annual Health Care Conference March 19, 2009
Slide 2: Forward-Looking Statement
Forward-Looking Statement [iamm The statements in this presentation that relate to future plans, events or og eS are Ores statements, which are eee ‘0 the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements involve significant risks and uncer
Slide 3: Company Profile
Company Profile = Palatin is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems.
Slide 4: Palatin Pipeline / March Status
Palatin Pipeline / March 09 Status [aan Sexual Dysfunction PL-6983 Es GSSsSSseSsssssssasssese=! es Heart Failure PL-3994 Obesity / Diabetes (AstraZeneca) MCR-4 Compound
Slide 5: Melanocortin Sexual Dysfunction Program
Melanocortin Sexual Dysfunction Program
Slide 6: Sexual Dysfunction Program Overview
Sexual Dysfunction Program Overview — > Palatin has extensive clinical experience with bremelanotide (BMT) an MCR-4 peptide agonist for the treatment of both Erectile Dysfunction (ED) and Female Sexual Dysfunction (FSD) — Evaluated in over 2000 patients — Demonstrated efficacy as a treatment for bot
Slide 7: Bremelanotide ED Program
Bremelanotide ED Program > Multiple BMT ED studies have demonstrated efficacy in a broad range of patients including those non-responsive to PDES inhibitor treatment Safarinejad and Hosseini; Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study; J U
Slide 8: Bremelanotide ED Market Opportunity
Bremelanotide ED ket Opportunity - i : 20% are “marginally 35% of patients satisfied” but have no are satisfied alternative treatment PDE-5 users options 35% are non- responsive to PDE-5 therapy and discontinue it Initial Target Population 10% PDE-5s are contraindicated Global peak sales: $533 milli
Slide 9: Bremelanotide
«—_—— Bremelanotide a Selective Nerve Signal Visual & Tactile Stimulation
Slide 10: BMT Improves Erectile Function in ED Patients
BMT Improves Erectile Function in ED Patients <> Change in EF Domain of IIEF > Placebo 5 7.5 10 12.5 15 Data presented at AUA Annual meeting 2007
Slide 11: Desirable Therapeutic Concentration
Desirable Therapeutic Concentration 11
Slide 12: Phase 2B in PDE5 inhibitor non-responsive patients
> > > > Phase 2B in PDES inhibitor non-responsive patients — Define subcutaneous (SC) doses for registration trials — Evaluate co-administration with a PDES inhibitor — Determine treatment effect to guide registration trials — Validated FDA accepted endpoints Protocols, Pl’s, CRO’s, timelines and bu
Slide 13: Key Points BMT ED Program
Key Points BMT ED Program = > Clinical and regulatory development path is straight forward > Significant clinical data in ED — Over 2,000 patients treated with BMT — Multiple ph. 2 studies show efficacy in PDES inhibitor non-responsive patients — Efficacy as monotherapy or as co-administration with
Slide 14: BMT Efficacy in Female Sexual Dysfunction
p < 0.001 p< 0.001 > Ph. 2 Efficacy in i Female Hypoactive 60: Arousal Disorder > Significant effects on arousal and desire 2 Cy & FSEP Arousal Success Rate % Change from Baseline > 40% of °° ain postmenopausal 20 women suffer from FSD i‘ > Large untapped market ‘ Data presented at American College
Slide 15: Natriuretic Peptide Program
Natriuretic Peptide Program
Slide 16: Heart Failure Overview
Heart Failure Overview > Heart failure (HF) symptoms and progression — Deregulation of BP - >50% of patients are hypertensive - Activation of Renin-Angiotensin-Aldosterone System (RAAS) — Abnormal sympathetic tone - Cardiac hypertrophy and remodeling — Fluid retention > Natriuretic Peptide System is
Slide 17: Natriuretic peptide system physiological effects
Neuropeptide hormone system that plays an important role in the regulation of cardiovascular homeostasis Physiological Effects * Down regulate Renin-Angiotensin-Aldosterone System Decrease Blood Pressure Suppression of Cardiac Hypertrophy & Remodeling Stimulation of Diuresis & Natriuresis Increased
Slide 18: Overview Natriuretic Program
Overview Natriuretic Program [iemm > Design and develop commercial candidates selective for NPR-A, NPR-B & NPR-A/B > PL-3994 Lead Product candidate — Selective for NPR-A — Increased metabolic stability — Once daily SC patient administration — Phase 2 drug development candidate > PL-3994 is in develo
Slide 19: Target heart failure patient population
> Chronic HF with history of frequent hospitalization for worsening symptoms > Adjunct to a diuretic and one or more of: ACEi, ARB, B-blocker, CRT > 3-6 month once daily subcutaneous treatment > Disease progression is not the main focus > Hemodynamic mechanisms likely to be key > Treatment goal to r
Slide 20: Daily Administration of PL-3994 Significantly Reduces Cardiac Remodeling
Daily Administration of PL-3994 Significantly <> Reduces Cardiac Remodeling cid Attenuation of RAAS Activation Heart Weight /Body Weight following 6 wooks of treatment 2K IC (saline) @ 2k1C (PL3994) Plasma aldosterone (pg/ml) AAS MY AA HY Time (days) The “2 Kidney, 1 Clip” model causes renovascular
Slide 21: Clinical Evidence that Cardiac Remodeling can be Prevented by NPR-A Activation
Clinical Evidence that Cardiac Remodeling can —kSy be Prevented by NPR-A Activation va > Two major lines of evidence suggest that chronic administration of NPR-A agonists will reduce cardiac remodeling in HF patients — Human genetic evidence + Pro-ANP and NPR-A receptor polymorphisms that cause lowe
Slide 22: PL-3994 Clinical Results
PL-3994 Clinical Results = > Phase 1 & 2a placebo-controlled dose escalation studies — Placebo and escalating doses of PL-3994 delivered SC — Endpoints — Safety, |SBP, fdiuresis, tnatriuresis, tcGMP plasma levels > Results — Well tolerated - no adverse or severe adverse events — Clear dose response
Slide 23: PL-3994 Next Steps
PL-3994 Next Steps — >Phase 2 dose ranging in HF outpatients with history of frequent hospitalization — Safety of repeat daily dosing — Reduction in re-hospitalization — Reduce plasma aldosterone levels — Imaging studies of slowing of ventricular remodeling — Evaluation of biomarkers of cardiac func
Slide 24: Developing in steps makes good sense
> Developing in 2 steps makes good sense — Sub-chronic followed by chronic — Manages risk — Less resources needed before approval > Sub-chronic treatment is an area of high unmet need with good scientific rationale > PL-3994 has suitable properties > Will develop for 3-6 month use and then extend in
Slide 25: Melanocortin Receptor Obesity Program
Melanocortin 4 Receptor Obesity Program > Partnered with AstraZeneca > Program objective is to identify compounds with the following profile — Reduce food intake and body fat — Reduce plasma glucose and insulin levels — Excellent bioavailability and stability profile — No increase in BP — No erectog
Slide 26: AstraZeneca licensing and research collaboration
» AstraZeneca is a global pharmaceutical company with a strong emphasis in metabolic disease > Exclusive global licensing and research collaboration — Covers discovery and development of compounds to treat obesity and related diseases targeting MCR’s > Terms include — $10M upfront — Up to $300M in p
Slide 27: Melanocortins and Obesity Overview
Melanocortins and Obesity Overview Loss of function mutations > Obesii arcuate nucleus , a n Stimulates MC4R MC4R-KO mice > hyperphagic and obese MC4 receptor mutations most common monogenic form of obesity in humans hypothalamus Ve Decreased Food Intake XN a-MSH and MT-II V Food Intake AGRP * Food
Slide 28: Food Consumption
Food Consumption GN Vehide- DO Ge Vehide - KO [= PLS903 @0.1-DIO = PL5903 @0.1 - KO Gam PL5S903@1.0-DIO mmm P5903 @1.0-kO 28
Slide 29: Ticker Symbol NYSE AMEX: PTN
Ticker Symbol NYSE AMEX: PTN 52-Week Price Range $0.06 - $1.05 Shares Outstanding as of 12/31/08 > Common 87M > Fully Diluted 101M Market Capitalization 12/08 $7.8M Cash and Investments Balance as of 12/31/08 $6.3M 29
Slide 30: Palatin Technologies
<> PALATIN TECHNOLOGIES
Palatin Technologies — Cowen and Company 29th Annual Health Care Conference (March 2009) on 6ix